More on JNJ

- Summary
- Chart
- Profile
- Historical


- Earnings (+0.9% Growth)
- Ratings (5.2 Score)
- Holders
- Dividends (3.1% Yield)
- Event Driven Deals
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (1/23/24)
- M&A (12/31/20 *Est)
- M&A (3/31/23 *Est)
- Conference (1/8/2024)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

JNJ Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 18.21B
Marketable securities
Accounts receivable, trade, less allowances for doubtful accounts $327 (2010, $340) 11.8B
Inventories (Note 2) 8.49B
Deferred taxes on income
Prepaid expenses and other receivables 2.6B
Total current assets 63.32B
Property, plant and equipment at cost 38.37B
Less: accumulated depreciation -22.28B
Property, plant and equipment, net 16.1B
Intangible assets, net (Note 3) 27.64B
Goodwill, net (Note 3) 23.17B
Deferred taxes on income 5.9B
Other assets 4.25B
Total assets 140.37B
Current liabilities:
Loans and notes payable 3.44B
Accounts payable 5.97B
Accrued liabilities 5.28B
Accrued rebates, returns and promotions 5.18B
Accrued compensation and employee related obligations 2.55B
Accrued taxes on income 798M
Total current liabilities 23.23B
Long-term debt (Note 4) 23.55B
Deferred taxes on income 3.19B
Employee related obligations 8.22B
Other liabilities 9.41B
Total liabilities 67.6B
Shareholders' equity:
Common stock - par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3.12B
Accumulated other comprehensive income (Note 7) -12.72B
Retained earnings 108.86B
Less: common stock held in treasury, at cost (379,263,000 and 381,746,000 shares) 26.5B
Total shareholders' equity 72.77B
Total liabilities and shareholders' equity 140.37B